Current treatment concepts of Philadelphia-negative MPN

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 44-55

  Wolf, D ^a,b   Rudzki, J ^a,b   Gastl, G ^a  

^a Internal Medicine V   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Jak2; Philadelphia negative mpn; Treatment concepts

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; AZACITIDINE; BEVACIZUMAB; CHLORAMBUCIL; CYTOTOXIC AGENT; DANAZOL; DASATINIB; HYDROXYUREA; IMATINIB; INCB 18424; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MEPOLIZUMAB; MIDOSTAURIN; NILOTINIB; PEGINTERFERON ALPHA; PHOSPHORUS 32; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POMALIDOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TG 101348; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; XL 019;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMNESIA; ANEMIA; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EOSINOPHILIC LEUKEMIA; FATIGUE; FLU LIKE SYNDROME; GENE MUTATION; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; INSOMNIA; LOW DRUG DOSE; MASTOCYTOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; RASH; REVIEW; SIDE EFFECT; SPLEEN SIZE; SYMPTOM; SYSTEMIC MASTOCYTOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; VEIN THROMBOSIS; WEIGHT REDUCTION;

ANIMALS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MUTATION;

EID: 78951485869     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743592     Document Type: Review

References (94)

1. Tefferi, A.; Thiele, J.; Orazi, A.; Kvasnicka, H. M.; Barbui, T.; Hanson, C. A.; Barosi, G.; Verstovsek, S.; Birgegard, G.; Mesa, R.; Reilly, J. T.; Gisslinger, H.; Vannucchi, A. M.; Cervantes, F.; Finazzi, G.; Hoffman, R.; Gilliland, D. G.; Bloomfield, C. D.; Vardiman, J. W. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110, 1092-1097.
2. Wilkins, B. S.; Erber, W. N.; Bareford, D.; Buck, G.; Wheatley, K.; East, C. L.; Paul, B.; Harrison, C. N.; Green, A. R.; Campbell, P. J. Bone marrow pathology in essential thrombocythemia: interob-server reliability and utility for identifying disease subtypes. Blood 2008, 111, 60-70.
3. Cortelazzo, S.; Viero, P.; Finazzi, G.; D'Emilio, A.; Rodeghiero, F.; Barbui, T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 1990, 8, 556-562.
4. Marchioli, R.; Finazzi, G.; Landolfi, R.; Kutti, J.; Gisslinger, H.; Patrono, C.; Marilus, R.; Villegas, A.; Tognoni, G.; Barbui, T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 2005, 23, 2224-2232.
5. Barbui, T.; Finazzi, G. When and how to treat essential thrombocythemia. N. Engl. J. Med. 2005, 353, 85-86.
6. Carobbio, A.; Antonioli, E.; Guglielmelli, P.; Vannucchi, A. M.; Delaini, F.; Guerini, V.; Finazzi, G.; Rambaldi, A.; Barbui, T. Leukocytosis and risk stratification assessment in essential thrombo-cythemia. J. Clin. Oncol. 2008, 26, 2732-2736.
7. Carobbio, A.; Finazzi, G.; Antonioli, E.; Guglielmelli, P.; Vannucchi, A. M.; Delaini, F.; Guerini, V.; Ruggeri, M.; Rodeghiero, F.; Rambaldi, A.; Barbui, T. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008, 112, 3135-3137.
8. Carobbio, A.; Finazzi, G.; Guerini, V.; Spinelli, O.; Delaini, F.; Marchioli, R.; Borrelli, G.; Rambaldi, A.; Barbui, T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007, 109, 2310-2313.
9. Antonioli, E.; Guglielmelli, P.; Pancrazzi, A.; Bogani, C.; Verrucci, M.; Ponziani, V.; Longo, G.; Bosi, A.; Vannucchi, A. M. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005, 19, 1847-1849.
10. Antonioli, E.; Guglielmelli, P.; Poli, G.; Bogani, C.; Pancrazzi, A.; Longo, G.; Ponziani, V.; Tozzi, L.; Pieri, L.; Santini, V.; Bosi, A.; Vannucchi, A. M. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008, 93, 41-48.
11. Austin, S. K.; Lambert, J. R. The JAK2 V617F mutation and thrombosis. Br. J. Haematol. 2008, 143, 307-320.
12. Dahabreh, I. J.; Zoi, K.; Giannouli, S.; Zoi, C.; Loukopoulos, D.; Voulgarelis, M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk. Res. 2009, 33, 67-73.
13. Ziakas, P. D. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008, 93(9), 1412-1414.
14. Barbui, T.; Barosi, G.; Grossi, A.; Gugliotta, L.; Liberato, L. N.; Marchetti, M.; Mazzucconi, M. G.; Rodeghiero, F.; Tura, S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004, 89, 215-232.
15. Barosi, G.; Birgegard, G.; Finazzi, G.; Griesshammer, M.; Harrison, C.; Hasselbalch, H. C.; Kiladjian, J. J.; Lengfelder, E.; McMullin, M. F.; Passamonti, F.; Reilly, J. T.; Vannucchi, A. M.; Barbui, T. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009, 113, 4829-4833.
16. Landolfi, R.; Marchioli, R.; Kutti, J.; Gisslinger, H.; Tognoni, G.; Patrono, C.; Barbui, T. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 2004, 350, 114-124.
17. Pearson, T. C.; Wetherley-Mein, G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978, 2, 1219-1222.
18. Patrono, C.; Garcia Rodriguez, L. A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353, 2373-2383.
19. Elliott, M. A.; Tefferi, A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br. J. Haematol. 2005, 128, 275-290.
20. Chan, F. K.; Ching, J. Y.; Hung, L. C.; Wong, V. W.; Leung, V. K.; Kung, N. N.; Hui, A. J.; Wu, J. C.; Leung, W. K.; Lee, V. W.; Lee, K. K.; Lee, Y. T.; Lau, J. Y.; To, K. F.; Chan, H. L.; Chung, S. C.; Sung, J. J. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 2005, 352, 238-244.
21. Cortelazzo, S.; Finazzi, G.; Ruggeri, M.; Vestri, O.; Galli, M.; Rodeghiero, F.; Barbui, T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 1995, 332, 1132-1136.
22. Harrison, C. N.; Campbell, P. J.; Buck, G.; Wheatley, K.; East, C. L.; Bareford, D.; Wilkins, B. S.; van der Walt, J. D.; Reilly, J. T.; Grigg, A. P.; Revell, P.; Woodcock, B. E.; Green, A. R. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 2005, 353, 33-45.
23. Lengfelder, E.; Griesshammer, M.; Hehlmann, R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk. Lymphoma 1996, 22 Suppl 1, 135-142.
24. Barbui, T.; Finazzi, G. Myeloproliferative disease in pregnancy and other management issues. Hematol. Am. Soc. Hematol. Educ. Program 2006, 246-252.
25. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann. Intern. Med. 1995, 123, 656-664.
26. Chievitz, E.; Thiede, T. Complications and causes of death in polycythaemia vera. Acta. Med. Scand. 1962, 172, 513-523.
27. Finazzi, G.; Caruso, V.; Marchioli, R.; Capnist, G.; Chisesi, T.; Finelli, C.; Gugliotta, L.; Landolfi, R.; Kutti, J.; Gisslinger, H.; Marilus, R.; Patrono, C.; Pogliani, E. M.; Randi, M. L.; Villegas, A.; Tognoni, G.; Barbui, T. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005, 105, 2664-2670.
28. Di Nisio, M.; Barbui, T.; Di Gennaro, L.; Borrelli, G.; Finazzi, G.; Landolfi, R.; Leone, G.; Marfisi, R.; Porreca, E.; Ruggeri, M.; Rutjes, A. W.; Tognoni, G.; Vannucchi, A. M.; Marchioli, R. The haematocrit and platelet target in polycythemia vera. Br. J. Haematol. 2007, 136, 249-259.
29. Berk, P. D.; Goldberg, J. D.; Donovan, P. B.; Fruchtman, S. M.; Berlin, N. I.; Wasserman, L. R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hematol. 1986, 23, 132-143.
30. Thomas, D. J.; Marshall, J.; Russell, R. W.; Wetherley-Mein, G.; du Boulay, G. H.; Pearson, T. C.; Symon, L.; Zilkha, E. Effect of haematocrit on cerebral blood-flow in man. Lancet 1977, 2, 941-943.
31. Silver, R. T. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin. Hematol. 1997, 34, 40-50.
32. Silver, R. T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006, 107, 451-458.
33. Quintas-Cardama, A.; Kantarjian, H.; Manshouri, T.; Luthra, R.; Estrov, Z.; Pierce, S.; Richie, M. A.; Borthakur, G.; Konopleva, M.; Cortes, J.; Verstovsek, S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 2009, 27, 5418-5424.
34. Cervantes, F.; Barosi, G.; Demory, J. L.; Reilly, J.; Guarnone, R.; Dupriez, B.; Pereira, A.; Montserrat, E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br. J. Haematol. 1998, 102, 684-690.
35. Cervantes, F.; Dupriez, B.; Pereira, A.; Passamonti, F.; Reilly, J. T.; Morra, E.; Vannucchi, A. M.; Mesa, R. A.; Demory, J. L.; Barosi, G.; Rumi, E.; Tefferi, A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113, 2895-2901.
36. Dupriez, B.; Morel, P.; Demory, J. L.; Lai, J. L.; Simon, M.; Plantier, I.; Bauters, F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88, 1013-1018.
37. Mesa, R. A.; Nagorney, D. S.; Schwager, S.; Allred, J.; Tefferi, A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006, 107, 361-370.
38. Tam, C. S.; Abruzzo, L. V.; Lin, K. I.; Cortes, J.; Lynn, A.; Keating, M. J.; Thomas, D. A.; Pierce, S.; Kantarjian, H.; Verstovsek, S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009, 113, 4171-4178.
39. Daly, A.; Song, K.; Nevill, T.; Nantel, S.; Toze, C.; Hogge, D.; Forrest, D.; Lavoie, J.; Sutherland, H.; Shepherd, J.; Hasegawa, W.; Lipton, J.; Messner, H.; Kiss, T. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003, 32, 35-40.
40. Deeg, H. J.; Gooley, T. A.; Flowers, M. E.; Sale, G. E.; Slattery, J. T.; Anasetti, C.; Chauncey, T. R.; Doney, K.; Georges, G. E.; Kiem, H. P.; Martin, P. J.; Petersdorf, E. W.; Radich, J.; Sanders, J. E.; Sandmaier, B. M.; Warren, E. H.; Witherspoon, R. P.; Storb, R.; Appelbaum, F. R. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102, 3912-3918.
41. Guardiola, P.; Anderson, J. E.; Bandini, G.; Cervantes, F.; Runde, V.; Arcese, W.; Bacigalupo, A.; Przepiorka, D.; O'Donnell, M. R.; Polchi, P.; Buzyn, A.; Sutton, L.; Cazals-Hatem, D.; Sale, G.; de Witte, T.; Deeg, H. J.; Gluckman, E. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93, 2831-2838.
42. Rondelli, D.; Barosi, G.; Bacigalupo, A.; Prchal, J. T.; Popat, U.; Alessandrino, E. P.; Spivak, J. L.; Smith, B. D.; Klingemann, H. G.; Fruchtman, S.; Hoffman, R. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediateor high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105, 4115-4119.
43. Hessling, J.; Kroger, N.; Werner, M.; Zabelina, T.; Hansen, A.; Kordes, U.; Ayuk, F. A.; Renges, H.; Panse, J.; Erttmann, R.; Zander, A. R. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2002, 119, 769-772.
44. Kroger, N.; Zabelina, T.; Schieder, H.; Panse, J.; Ayuk, F.; Stute, N.; Fehse, N.; Waschke, O.; Fehse, B.; Kvasnicka, H. M.; Thiele, J.; Zander, A. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br. J. Haematol. 2005, 128, 690-697.
45. Kroger, N.; Holler, E.; Kobbe, G.; Bornhauser, M.; Schwerdtfeger, R.; Baurmann, H.; Nagler, A.; Bethge, W.; Stelljes, M.; Uharek, L.; Wandt, H.; Burchert, A.; Corradini, P.; Schubert, J.; Kaufmann, M.; Dreger, P.; Wulf, G. G.; Einsele, H.; Zabelina, T.; Kvasnicka, H. M.; Thiele, J.; Brand, R.; Zander, A. R.; Niederwieser, D.; de Witte, T. M. Allogeneic stem cell transplantation after reducedintensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009, 114, 5264-5270.
46. Patriarca, F.; Bacigalupo, A.; Sperotto, A.; Isola, M.; Soldano, F.; Bruno, B.; van Lint, M. T.; Iori, A. P.; Santarone, S.; Porretto, F.; Pioltelli, P.; Visani, G.; Iacopino, P.; Fanin, R.; Bosi, A. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20- year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008, 93, 1514-1522.
47. Rodriguez, J. N.; Martino, M. L.; Dieguez, J. C.; Prados, D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998, 83, 616-621.
48. Cervantes, F.; Alvarez-Larran, A.; Domingo, A.; Arellano-Rodrigo, E.; Montserrat, E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br. J. Haematol. 2005, 129, 771-775.
49. Cervantes, F.; Hernandez-Boluda, J. C.; Alvarez, A.; Nadal, E.; Montserrat, E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000, 85, 595-599.
50. Abgrall, J. F.; Guibaud, I.; Bastie, J. N.; Flesch, M.; Rossi, J. F.; Lacotte-Thierry, L.; Boyer, F.; Casassus, P.; Slama, B.; Berthou, C.; Rodon, P.; Leporrier, M.; Villemagne, B.; Himberlin, C.; Ghomari, K.; Larosa, F.; Rollot, F.; Dugay, J.; Allard, C.; Maigre, M.; Isnard, F.; Zerbib, R.; Cauvin, J. M. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006, 91, 1027-1032.
51. Tefferi, A.; Cortes, J.; Verstovsek, S.; Mesa, R. A.; Thomas, D.; Lasho, T. L.; Hogan, W. J.; Litzow, M. R.; Allred, J. B.; Jones, D.; Byrne, C.; Zeldis, J. B.; Ketterling, R. P.; McClure, R. F.; Giles, F.; Kantarjian, H. M. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108, 1158-1164.
52. Tefferi, A.; Verstovsek, S.; Barosi, G.; Passamonti, F.; Roboz, G. J.; Gisslinger, H.; Paquette, R. L.; Cervantes, F.; Rivera, C. E.; Deeg, H. J.; Thiele, J.; Kvasnicka, H. M.; Vardiman, J. W.; Zhang, Y.; Bekele, B. N.; Mesa, R. A.; Gale, R. P.; Kantarjian, H. M. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J. Clin. Oncol. 2009, 27, 4563-4569.
53. Verstovsek, S.; Kantarjian, H.; Mesa, R. A.; Pardanani, A. D.; Cortes-Franco, J.; Thomas, D. A.; Estrov, Z.; Fridman, J. S.; Bradley, E. C.; Erickson-Viitanen, S.; Vaddi, K.; Levy, R.; Tefferi, A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363, 1117-1127.
54. Santos, F. P.; Kantarjian, H. M.; Jain, N.; Manshouri, T.; Thomas, D. A.; Garcia-Manero, G.; Kennedy, D.; Estrov, Z.; Cortes, J.; Verstovsek, S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115, 1131-1136.
55. Tefferi, A.; Mesa, R. A.; Nagorney, D. M.; Schroeder, G.; Silverstein, M. N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000, 95, 2226-2233.
56. Quintas-Cardama, A.; Tong, W.; Kantarjian, H.; Thomas, D.; Ravandi, F.; Kornblau, S.; Manshouri, T.; Cortes, J. E.; Garcia-Manero, G.; Verstovsek, S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008, 22, 965-970.
57. Giles, F. J.; Cooper, M. A.; Silverman, L.; Karp, J. E.; Lancet, J. E.; Zangari, M.; Shami, P. J.; Khan, K. D.; Hannah, A. L.; Cherrington, J. M.; Thomas, D. A.; Garcia-Manero, G.; Albitar, M.; Kantarjian, H. M.; Stopeck, A. T. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 2003, 97, 1920-1928.
58. Giles, F. J.; List, A. F.; Carroll, M.; Cortes, J. E.; Valickas, J.; Chen, B. L.; Masson, E.; Jacques, C.; Laurent, D.; Albitar, M.; Feldman, E. J.; Roboz, G. J. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk. Res. 2007, 31, 891-897.
59. Cools, J.; DeAngelo, D. J.; Gotlib, J.; Stover, E. H.; Legare, R. D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky, I.; Griffin, J. D.; Cross, N. C.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S. L.; Schmid, J.; Rose, M.; Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodarska, I.; Kantarjian, H.; Marynen, P.; Coutre, S. E.; Stone, R.; Gilliland, D. G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348, 1201-1214.
60. Griffin, J. H.; Leung, J.; Bruner, R. J.; Caligiuri, M. A.; Briesewitz, R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 7830-7835.
61. Simon, H. U.; Plotz, S. G.; Dummer, R.; Blaser, K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N. Engl. J. Med. 1999, 341, 1112-1120.
62. Baccarani, M.; Cilloni, D.; Rondoni, M.; Ottaviani, E.; Messa, F.; Merante, S.; Tiribelli, M.; Buccisano, F.; Testoni, N.; Gottardi, E.; de Vivo, A.; Giugliano, E.; Iacobucci, I.; Paolini, S.; Soverini, S.; Rosti, G.; Rancati, F.; Astolfi, C.; Pane, F.; Saglio, G.; Martinelli, G. The efficacy of imatinib mesylate in patients with FIP1L1- PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92, 1173-1179.
63. Roche-Lestienne, C.; Lepers, S.; Soenen-Cornu, V.; Kahn, J. E.; Lai, J. L.; Hachulla, E.; Drupt, F.; Demarty, A. L.; Roumier, A. S.; Gardembas, M.; Dib, M.; Philippe, N.; Cambier, N.; Barete, S.; Libersa, C.; Bletry, O.; Hatron, P. Y.; Quesnel, B.; Rose, C.; Maloum, K.; Blanchet, O.; Fenaux, P.; Prin, L.; Preudhomme, C. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005, 19, 792-798.
64. Tefferi, A.; Vardiman, J. W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22, 14-22.
65. Rousselot, P.; Huguet, F.; Rea, D.; Legros, L.; Cayuela, J. M.; Maarek, O.; Blanchet, O.; Marit, G.; Gluckman, E.; Reiffers, J.; Gardembas, M.; Mahon, F. X. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109, 58-60.
66. Jain, N.; Cortes, J.; Quintas-Cardama, A.; Manshouri, T.; Luthra, R.; Garcia-Manero, G.; Kantarjian, H.; Verstovsek, S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk. Res. 2009, 33, 837-839.
67. Metzgeroth, G.; Walz, C.; Erben, P.; Popp, H.; Schmitt-Graeff, A.; Haferlach, C.; Fabarius, A.; Schnittger, S.; Grimwade, D.; Cross, N. C.; Hehlmann, R.; Hochhaus, A.; Reiter, A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br. J. Haematol. 2008, 143, 707-715.
68. Helbig, G.; Stella-Holowiecka, B.; Majewski, M.; Calbecka, M.; Gajkowska, J.; Klimkiewicz, R.; Moskwa, A.; Grzegorczyk, J.; Lewandowska, M.; Holowiecki, J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br. J. Haematol. 2008, 141, 200-204.
69. Simon, D.; Salemi, S.; Yousefi, S.; Simon, H. U. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J. Allergy Clin. Immunol. 2008, 121, 1054-1056.
70. Cools, J.; Stover, E. H.; Boulton, C. L.; Gotlib, J.; Legare, R. D.; Amaral, S. M.; Curley, D. P.; Duclos, N.; Rowan, R.; Kutok, J. L.; Lee, B. H.; Williams, I. R.; Coutre, S. E.; Stone, R. M.; DeAngelo, D. J.; Marynen, P.; Manley, P. W.; Meyer, T.; Fabbro, D.; Neuberg, D.; Weisberg, E.; Griffin, J. D.; Gilliland, D. G. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1- PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3, 459-469.
71. Lierman, E.; Folens, C.; Stover, E. H.; Mentens, N.; Van Miegroet, H.; Scheers, W.; Boogaerts, M.; Vandenberghe, P.; Marynen, P.; Cools, J. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108, 1374-1376.
72. Verstovsek, S.; Giles, F. J.; Quintas-Cardama, A.; Manshouri, T.; Huynh, L.; Manley, P.; Cortes, J.; Tefferi, A.; Kantarjian, H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk. Res. 2006, 30, 1499-1505.
73. Kalac, M.; Quintas-Cardama, A.; Vrhovac, R.; Kantarjian, H.; Verstovsek, S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007, 110, 955-964.
74. Klion, A. D.; Law, M. A.; Noel, P.; Kim, Y. J.; Haverty, T. P.; Nutman, T. B. Safety and efficacy of the monoclonal antiinterleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103, 2939-2941.
75. Rothenberg, M. E.; Klion, A. D.; Roufosse, F. E.; Kahn, J. E.; Weller, P. F.; Simon, H. U.; Schwartz, L. B.; Rosenwasser, L. J.; Ring, J.; Griffin, E. F.; Haig, A. E.; Frewer, P. I.; Parkin, J. M.; Gleich, G. J. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 2008, 358, 1215-1228.
76. Roufosse, F. E.; Goldman, M.; Cogan, E. Hypereosinophilic syndromes. Orphanet J. Rare Dis. 2007, 2, 37.
77. Florian, S.; Esterbauer, H.; Binder, T.; Mullauer, L.; Haas, O. A.; Sperr, W. R.; Sillaber, C.; Valent, P. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk. Res. 2006, 30, 1201-1205.
78. Fricker, M.; Helbling, A.; Schwartz, L.; Muller, U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J. Allergy Clin. Immunol. 1997, 100, 11-15.
79. Castells, M.; Austen, K. F. Mastocytosis: mediator-related signs and symptoms. Int. Arch. Allergy Immunol. 2002, 127, 147-152.
80. Sperr, W. R.; Horny, H. P.; Lechner, K.; Valent, P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma 2000, 37, 473-486.
81. Sperr, W. R.; Horny, H. P.; Valent, P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 2002, 127, 140-142.
82. Hauswirth, A. W.; Sperr, W. R.; Ghannadan, M.; Schernthaner, G. H.; Jordan, J. H.; Fritsche-Polanz, R.; Simonitsch-Klupp, I.; Fodinger, M.; Lechner, K.; Valent, P. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk. Res. 2002, 26, 601-606.
83. Valent, P.; Akin, C.; Sperr, W. R.; Escribano, L.; Arock, M.; Horny, H. P.; Bennett, J. M.; Metcalfe, D. D. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 2003, 27, 635-641.
84. Casassus, P.; Caillat-Vigneron, N.; Martin, A.; Simon, J.; Gallais, V.; Beaudry, P.; Eclache, V.; Laroche, L.; Lortholary, P.; Raphael, M.; Guillevin, L.; Lortholary, O. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 2002, 119, 1090-1097.
85. Delaporte, E.; Pierard, E.; Wolthers, B. G.; Desreumaux, P.; Janin, A.; Cortot, A.; Piette, F.; Bergoend, H. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br. J. Dermatol. 1995, 132, 479-482.
86. Kluin-Nelemans, H. C.; Oldhoff, J. M.; Van Doormaal, J. J.; Van 't Wout, J. W.; Verhoef, G.; Gerrits, W. B.; van Dobbenburgh, O. A.; Pasmans, S. G.; Fijnheer, R. Cladribine therapy for systemic mastocytosis. Blood 2003, 102, 4270-4276.
87. Pardanani, A.; Hoffbrand, A. V.; Butterfield, J. H.; Tefferi, A. Treatment of systemic mast cell disease with 2- chlorodeoxyadenosine. Leuk. Res. 2004, 28, 127-131.
88. Pardanani, A.; Reeder, T.; Porrata, L. F.; Li, C. Y.; Tazelaar, H. D.; Baxter, E. J.; Witzig, T. E.; Cross, N. C.; Tefferi, A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101, 3391-3397.
89. Shah, N. P.; Lee, F. Y.; Luo, R.; Jiang, Y.; Donker, M.; Akin, C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108, 286-291.
90. Gleixner, K. V.; Mayerhofer, M.; Aichberger, K. J.; Derdak, S.; Sonneck, K.; Bohm, A.; Gruze, A.; Samorapoompichit, P.; Manley, P. W.; Fabbro, D.; Pickl, W. F.; Sillaber, C.; Valent, P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006, 107, 752-759.
91. Gotlib, J.; Berube, C.; Growney, J. D.; Chen, C. C.; George, T. I.; Williams, C.; Kajiguchi, T.; Ruan, J.; Lilleberg, S. L.; Durocher, J. A.; Lichy, J. H.; Wang, Y.; Cohen, P. S.; Arber, D. A.; Heinrich, M. C.; Neckers, L.; Galli, S. J.; Gilliland, D. G.; Coutre, S. E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106, 2865-2870.
92. von Bubnoff, N.; Gorantla, S. H.; Kancha, R. K.; Lordick, F.; Peschel, C.; Duyster, J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005, 19(9), 1670-1671.
93. Sperr, W. R.; Drach, J.; Hauswirth, A. W.; Ackermann, J.; Mitterbauer, M.; Mitterbauer, G.; Foedinger, M.; Fonatsch, C.; Simonitsch-Klupp, I.; Kalhs, P.; Valent, P. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin. Cancer Res. 2005, 11, 6787-6792.
94. Nakamura, R.; Chakrabarti, S.; Akin, C.; Robyn, J.; Bahceci, E.; Greene, A.; Childs, R.; Dunbar, C. E.; Metcalfe, D. D.; Barrett, A. J. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006, 37, 353-358.